OAT PINs and DINs
Last updated: July 17, 2023
On this page
These tables provide product identification numbers (PINs) and drug identification numbers (DINs) for PharmaCare claims for opioid agonist treatment (OAT).
PINs are for OAT claims only. If a prescription is for pain, enter the transaction in PharmaNet with the corresponding DIN. Do not use OAT PINs for pain indications.
As of June 6, 2023, regular benefit OAT is covered under plans B, C, G and Z. Non-benefit OAT is covered under Plan B, C, G, W and Z.
Interaction fees
PharmaCare pays an interaction fee to pharmacies that are a) enrolled in the OAT provider sub-class; and b) dispensing methadone with direct interaction. The only eligible claims are for witnessed ingestion of methadone.
Exceptional Plan Z coverage
Exceptional Plan Z coverage of OAT is available to people living in B.C. who are not yet fully enrolled in MSP. See Exceptional Plan Z coverage for OAT on the Plan Z web page.
Potential coverage issues for non-benefit OAT Special Authority
After June 6, 2023, patients should receive 100% coverage for non-benefit OAT if they have active exceptional SA in place. Pharmacists should be aware that patients with exceptional SA for non-benefit OAT (i.e., Methadose® sugar-free/dye-free, compounded methadone, Suboxone® 12 mg and 16 mg SL tabs, Suboxone® film) may experience a change from 100% coverage to partial or no coverage at the pharmacy, despite having an active SA approval. This could happen, for instance, following an income review or January 1 deductible update for patients covered by Fair PharmaCare. This is due to the technicalities of entering SAs to cover non-benefit OAT under Plan Z.
Pharmacists and prescribers should call the HIBC Help Desk if they believe that someone with an SA for non-benefit OAT is not receiving the appropriate coverage. Help Desk staff will determine whether the SA is active and, if so, will contact the SA team to determine coverage issues and re-instatement. If the SA has indeed expired, the prescriber will need to submit a new SA request.
Regular benefit OAT
Methadone
Methadone claim submission requirements
- Claim quantity must be submitted as total mL
- SIG must include dose in mg and mL, e.g., "Take 5 mL (50 mg) once daily."
- SIG must include the start and end dates of the prescription.
- Carries must be claimed as single multiple-day supply for drug cost, plus a single dispensing fee.
- Split doses must be claimed as a single multiple-dose claim for drug cost, plus a single dispensing fee.
- Maximum one dispensing fee and one interaction fee per patient per day.
Metadol-D™ 10 mg/mL (unflavoured) DIN 2244290 | PIN for OAT | Plan coverage |
---|---|---|
Metadol-D 10 mg/mL (unflavoured) - direct interaction | 67000005 | Plans B, C, G, and Z |
Metadol-D 10 mg/mL (unflavoured) - no direct interaction | 67000006 | |
Metadol-D 10 mg/mL (unflavoured) - direct interaction with delivery | 67000007 | |
Metadol-D 10 mg/mL (unflavoured) - no direct interaction with delivery | 67000008 |
Buprenorphine/naloxone, Sublocade® and Kadian®
Buprenorphine/naloxone, Sublocade® and Kadian® | DIN/PIN for OAT | Plan coverage | Claim submission requirements |
---|---|---|---|
buprenorphine/naloxone SL - 2 mg/0.5 mg generics | ACT 02453908 | Plans B, C, G, and Z No interaction fee paid for witnessed ingestion. |
|
PMS 02424851 | |||
buprenorphine/naloxone SL - 8 mg/2 mg generics | ACT 02453916 | ||
PMS 02424878 | |||
Kadian slow-release oral morphine 10 mg capsule | 22123349 (PIN) | Plans B, C, G, and Z No interaction fee paid for witnessed ingestion. |
|
Kadian slow-release oral morphine 20 mg capsule | 22123346 (PIN) | ||
Kadian slow-release oral morphine 50 mg capsule | 22123347 (PIN) | ||
Kadian slow-release oral morphine 100 mg capsule | 22123348 (PIN) | ||
Sublocade 100 mg/0.5 SOLER SYR | 02483084 | Plans B, C, G, and Z. Eligible for drug administration fee. |
|
Sublocade 300 mg/1.5 SOLER SYR | 02483092 |
Non-benefit OAT
Methadone
Compounded methadone 10 mg/mL | PIN for OAT | Plan coverage |
---|---|---|
Compounded methadone 10 mg/mL - direct interaction | 67000013 |
Last-resort, exceptional coverage available with Special Authority. |
Compounded methadone 10 mg/mL - direct interaction with delivery | 67000014 | |
Compounded methadone 10 mg/mL - no direct interaction | 67000016 | |
Compounded methadone 10 mg/mL - no direct interaction with delivery | 67000015 |
Suboxone®
Suboxone® | DIN/PIN for OAT | Plan coverage | Claim submission requirements |
---|---|---|---|
Partial benefit | |||
Suboxone buprenorphine/naloxone - 2 mg/0.5 mg SL | 02295695 | Partial benefit under Plan B, C, G and Z. No interaction fee paid for witnessed ingestion. |
|
Suboxone buprenorphine/naloxone - 8 mg/2 mg SL | 02295709 | ||
Non-benefit | |||
Suboxone buprenorphine/naloxone - 12 mg/3 mg SL | 02468085 | Exceptional Special Authority coverage required under plans Plan B, C, G, W and Z. No interaction fee paid for witnessed ingestion. |
|
Suboxone buprenorphine/naloxone - 16 mg/4 mg SL | 02468093 |
Situation | PIN |
---|---|
Clinic (ward) stock dose | 66128342 |
missed dose | 66128343 |
dose increased at clinic visit | 66128344 |
dose decreased at clinic visit | 66128345 |
buprenorphine/naloxone induction doses | 66128346 |
PharmaCare has partnered with the BC Pharmacy Association to provide an opioid agonist treatment (OAT) training program for community pharmacists. For further information, and to register for the training program, please visit www.bcpharmacy.ca.
More information on OAT and methadone formulations: BC Centre on Substance Use bulletin (PDF).